middle.news
Neuren Pharmaceuticals Posts 88% Profit Surge, Advances NNZ-2591 Phase 3 Trial
12:49am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Neuren Pharmaceuticals Posts 88% Profit Surge, Advances NNZ-2591 Phase 3 Trial
12:49am on Saturday 30th of August, 2025 AEST
Key Points
Net profit after tax rose 88% to A$15.0 million
Royalty revenue from Acadia’s DAYBUE™ increased 16% to A$28.3 million
Initiation of Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome
On-market share buy-back completed totaling A$39.6 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE